Study #2023-0876
A multicenter, randomized, double-blind, placebo controlled, phase 3 study of Ficlatuzumab in combination with Cetuximab in participants with recurrent or metastatic (r/m) Hpvnegative head and neck Squamous cell Carcinoma
MD Anderson Study Status
Enrolling
Treatment Agent
Ficlatuzumab, Cetuximab
Description
The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is that ficlatuzumab combined with cetuximab is superior to cetuximab alone in terms of progression-free survival and/or overall survival.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Study phase:
Phase III
Physician name:
Neal Akhave
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-866-403-3911
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.